RxDoctor Payments Data

Paulpoj Chiranand, MD

Retina Specialist · Chicago, ILNPI 1639377260

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (36.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Alimera Sciences, Inc. at 40.0% of the total. Reporting peaked in 2022 at $7,344 and has fallen 83.1% since, to $1,241 in 2025.

$16,842in general payments, 2019–2025

Across 105 payments — averaging $160.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alimera Sciences, Inc.$7K
  • AbbVie$6K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Alcon$948
  • Eyepoint US, Inc.$269
  • Apellis Pharmaceuticals, Inc.$234
  • plus $1K from 12 others
$19,400in research payments, 2019–2025

Across 4 payments — averaging $4850.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$10K
  • Eyepoint US, Inc.$9K

What the payments were for

  • Consulting fees$4,96529%
  • Speaking & faculty fees$6,20037%
  • Food & beverage$5,65334%
  • Entertainment$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,842 in reported general payments places this provider in the 75th percentile of 70 retina specialist providers in Illinois.

See all retina specialist providers in Illinois

Medicare billing

Part B allowed, 2024
$534,436
Medicare patients
296
Services billed
5,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate93$3,264
Brinzolamide12$1,676
Ketorolac Tromethamine58$1,610
Latanoprost146$1,546
Difluprednate14$1,538
Brimonidine Tartrate30$428
Atropine Sulfate13$336
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat11$248
Timolol Maleate50$244
Dorzolamide Hcl17$163

Paid to pharmacies, not to this prescriber.

Other retina specialist in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →